Back to search
Cardiovascular Disease and Lipoprotein(a)
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Cardiovascular Disease and Lipoprotein(a) trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Cardiovascular Disease and Lipoprotein(a) trials you may qualify forThis open-label extension study will provide post-trial access to pelacarsen (TQJ230) to participants who have successfully completed the double-blind parent st…
The primary objective is to evaluate the effect of olpasiran, compared to placebo, on the risk for coronary heart disease death (CHD death), myocardial infarcti…
The primary objective of this trial is to evaluate the effect of olpasiran, compared to placebo, on non-calcified plaque (NCP) volume as measured by Coronary Co…
The purpose of the study CTQJ230A12304, is to evaluate the efficacy, safety, and tolerability of pelacarsen (TQJ230) compared to placebo in participants with AS…
The main purpose of this study is to determine the safety and efficacy of DII235 in adults with elevated lipoprotein(a).
VT-10201 is an Open-label, Phase 1b, Single-ascending Dose Study That Will Evaluate the Safety of VERVE-102 Administered to Patients With Heterozygous Familial…
This is a study to evaluate the efficacy and safety of AZD0780 in adults with clinical ASCVD or who are at risk for a first ASCVD event and who have elevated LD…
The goal of this clinical trial is to test whether one pill that combines ezetimibe, rosuvastatin, and amlodipine can safely lower cholesterol and blood pressur…